CSIMarket
 
Universe Pharmaceuticals Inc  (NASDAQ: UPC)
Other Ticker:  
 
 
Price: $0.1840 $0.02 14.286%
Day's High: $0.245 Week Perf: -55.92 %
Day's Low: $ 0.16 30 Day Perf: -71.25 %
Volume (M): 144,297 52 Wk High: $ 4.93
Volume (M$): $ 26,551 52 Wk Avg: $1.79
Open: $0.21 52 Wk Low: $0.12



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 4
 Employees 100
 Revenues (TTM) (Millions $) 32
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc is a publicly-traded biopharmaceutical company that is focused on developing and commercializing innovative therapies for the treatment of various cancers and other serious diseases. The company was founded in 2008 and is headquartered in San Francisco, California.

The company's pipeline consists of several drug candidates that are in various stages of clinical development, including both small molecules and biologics. One of the company's most promising candidates is UNI-119, a small molecule inhibitor of a key signaling pathway that is overactivated in many types of cancer. Preclinical studies have shown that UNI-119 is highly effective against a wide range of cancer cells, and the drug is now in phase 1 clinical trials in patients with advanced solid tumors.

In addition to its work on cancer therapeutics, Universe Pharmaceuticals is also actively engaged in research and development in other areas of medicine. The company has recently announced efforts to expand its portfolio to include treatments for neurological disorders, such as Alzheimer's disease and Parkinson's disease.

The company has a strong focus on research and development and has invested considerable resources in building a state-of-the-art research facility to support its drug development efforts. The facility is staffed by an experienced team of scientists and clinicians who are dedicated to developing groundbreaking new therapies for some of the most challenging diseases facing patients today.

In terms of financials, Universe Pharmaceuticals has a market capitalization of over $1 billion and has achieved steady revenue growth over the last several years. The company's strong financial position has allowed it to continue making significant investments in its R&D efforts and has positioned it well to capitalize on its promising pipeline of drug candidates.

In summary, Universe Pharmaceuticals Inc is an innovative biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases. With a promising pipeline of drug candidates, a strong focus on R&D, and a commitment to improving patient outcomes, the company is well-positioned for continued growth and success in the industry.


   Company Address: 265 Jingjiu Avenue, Ji?an, Jiangxi 343100
   Company Phone Number: 86-0796-8403309   Stock Exchange / Ticker: NASDAQ UPC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -4.03%    
ENDPQ   -4.03%    
PFE   -1.76%    
PRGO   -1.95%    
TEVA   -3%    
VTRS   -2.81%    
• View Complete Report
   



23andme Holding Co

Robust 36.166% Top-line rise at ME in the fiscal time-frame ending December 31 2024

For the fiscal time-frame ending December 31 2024 company decreased a loss per share of $-2.01 per share compare to $-11.60 a year ago and Income per Share improved from $-46.40 per share from the preceding financial reporting period. The revenue jumped by 36.166 % to $59.83 million from $43.94 million in the similar financial reporting period a year ago and sequentially revenue surged by 37.826 % from $43.41 million. 23andme Holding Cos' revenue grew at higher rate compared to the the top-line at virtually all of the Major Pharmaceutical Preparations sector peers, in the third quarter of 2025 the majority corporations in Major Pharmaceutical Preparations sectors experienced an average revenue rise of 2.49% compared to the similar period a year before.

Prestige Consumer Healthcare Inc

The markets are digesting the 2.877%, increase at the company amid the October to December 31 2024 span

company achieved double digit profitability advance on moderate Revenue advance in the third quarter of 2025 earnings season, where income surged by 15.09 % to $1.22 per share, revenue advanced moderate by 2.877 % to $290.05 million from the comparable reporting season a year prior. In contrast to the Q2 revenue surged by 2.353 % from $283.38 million and income per share surged by 11.93 % from $1.09 per share. Prestige Consumer Healthcare Inc s' has evidently beaten its industry peers on the revenue angle, as the remainder of the Major Pharmaceutical Preparations industry express 2.49% during the matching time top-line advance so far.

Regeneron Pharmaceuticals Inc

Rewarding reporting season by REGN all along the financial time-frame closing Dec 31 2024

the Major Pharmaceutical Preparations company dealt with demise in eps, in the wake of Revenue growth in the financial time-frame closing Dec 31 2024, income fell by -22.49 % to $7.88 per share, while Revenue increased in double digits by 10.334 % to $3.79 billion, from the same reporting season a year before. REGNs' top-line, advancement in the fourth quarter of 2024 correlates positively to its Major Pharmaceutical Preparations industry peers, which had overall 0.63 % revenue growth during the same period yet.

Phibro Animal Health Corporation

growth, growth, growth by at the company over the October to December 31 2024 interval

Phibro Animal Health Corporation showed respectable growth in the Dec 31 2024 report, where earnings per share elevated on the another level by 166.67 % year on year to $0.08 per share and Revenue increased by 23.738 % to $308.87 million.

Teva Pharmaceutical Industries Limited

Observing the fourth quarter of 2024 performance, the company's had a unassuming -5.049 %, deterioration in revenue

For the October to December 31 2024 fiscal time-frame company Diminishing Returns have swelled of $-0.19 per share compare to $0.38 a year ago and EPS improved from $-0.39 per share from the prior reporting period. The revenue decreased by -5.049 % to $4.23 billion from $4.46 billion in the comparable reporting period a year ago and sequentially Revenue decreased by -2.309 % from $4.33 billion. The on averageMajor Pharmaceutical Preparations sector, recorded a top-line growth in the fourth quarter of 2024.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com